Medical biofilms

Biotechnology and Bioengineering

Volumn 100, Issue 1, 2008, Pages 1-18

  Bryers, James D ^a  

^a University of Washington   (United States)

Author keywords

Engineering immunity; Host immune response; Medical biofilms; Nosocomial infections

Indexed keywords

BIOMEDICAL ENGINEERING; BIOTECHNOLOGY; ECOSYSTEMS; ENGINEERING RESEARCH; MICROBIOLOGY;

ENGINEERING IMMUNITY; HOST IMMUNE RESPONSE; MEDICAL BIOFILMS; NOSOCOMIAL INFECTIONS;

BIOFILMS;

BIOMATERIAL; DNA VACCINE; GALLIUM; HYBRID PROTEIN; IMIPENEM; MACROGOL; N (3 OXODODECANOYL)HOMOSERINE LACTONE; PLASMID DNA; POLYACRYLIC ACID; RNA VACCINE; TOBRAMYCIN; VANCOMYCIN;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIGEN PRESENTATION; BACTERIAL CELL; BACTERIAL VIRULENCE; BIOFILM; BIOLUMINESCENCE; BIOMEDICAL ENGINEERING; CELL INTERACTION; CHRONIC INFLAMMATION; CONFOCAL LASER MICROSCOPY; CORROSION; CYSTIC FIBROSIS; DENDRITIC CELL; FOREIGN BODY REACTION; HEAT TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; IRON METABOLISM; MACROPHAGE FUNCTION; MATERIAL COATING; MATERIAL STATE; NONHUMAN; PHAGOCYTOSIS; POLYMERASE CHAIN REACTION; QUORUM SENSING; REVIEW; WOUND HEALING;

BACTERIAL ADHESION; BACTERIAL INFECTIONS; BIOFILMS; BIOREACTORS; DISINFECTION; EQUIPMENT CONTAMINATION; HUMANS; STERILIZATION;

EID: 42549164149     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21838     Document Type: Review

References (154)

1. An YH, Friedman RJ. 1998. Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res 43(3):338-348.
2. Anderson JM. 2001. Biological responses to materials. Annu Rev Mater Res 31:81-110.
3. Anderson CF, Mosser DM. 2002. A novel phenotype for an activated macrophage: The type 2 activated macrophage. J Leukoc Biol 72:101-106.
4. Ankenbauer R, Sriyosachati S, Cox. CD. 1985. Effects of siderophores on the growth of Pseudomonas aeruginosa in human serum and transferrin. Infect Immun 49:132-140.
5. Atkinson RA, Salah El Din AL, Kieffer B, Lefevre JF, Abdallah MA. 1998. Bacterial iron transport: 1H NMR determination of the three-dimensional structure of the gallium complex of pyoverdin G4R, the peptidic siderophore of Pseudomonas putida G4R. Biochemistry 37:15965-15973.
6. Bagge N, Schuster M, Hentzer M, Ciofu O, Givskov M, Greenberg EP, Høiby N. 2004. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production. Antimicrob Agents Chemother 48(4):1175-1187.
7. Bakaletz LO. 2007. Bacterial biofilms in otitis media: Evidence and relevance. Pediatr Infect Dis J 10-Suppl: S17-S19.
8. Banchereau J, Steinman RM. 1998. B and T lymphocytes are the mediators of immunity, but their function is under the control of dendritic cells. Dendritic cells in the periphery. Nature 392:245-252.
9. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. 2000. Immunobiology of dendritic cells. Ann Rev Immunol 18:767-811.
10. Barclay R, Ratledge C. 1986. Participation of iron on the growth inhibition of pathogenic strains of Mycobacterium avium and M. paratuberculosis in serum. Zentralbl Bakteriol Mikrobiol Hyg [A] 262:189-194.
11. Bauer TW, Parvizi J, Kobayashi N, Krebs V. 2006. Diagnosis of periprosthetic infection. J Bone Joint Surg Am 88(4):869-882.
12. Beaudoin D, Bryers JD, Cunningham AB, Peretti SW. 1998a. Mobilization of broad host range plasmid from Pseudomonas putida to established biofilm of Bacillus azotoformans. I. Experiments. Biotechnol Bioeng 57:272-279.
13. Beaudoin D, Bryers JD, Cunningham AB, Peretti SW. 1998b. Mobilization of broad host range plasmid from Pseudomonas putida to established biofilm of Bacillus azotoformans. II. Modeling. Biotechnol Bioeng 57:280-286.
14. Bennewitz NL, Babensee JL. 2005. The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen. Biomaterials 26:2991-2999.
15. Bjarnsholt T, Givskov M. 2007. Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens. Philos Trans R Soc Lond B Biol Sci 362(1483):1213-1222.
16. Boles BR, Thoendel M, Singh PK. 2005. Rhamnolipids mediate detachment of Pseudomonas aeruginosa from biofilms. Mol Microbiol 57:1210-1223.
17. Bonini C, Lee SP, Riddell SR, Greenberg PD. 2001. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 166:5250-5257.
18. Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME. 2007. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immunol Med Microbiol. 2007 Dec 11; [Epub ahead of print] PMID: 18081847.
19. Branda SS, Vik S, Friedman L, Kolter R. 2005. Biofilms: The matrix revisited. Trends Microbiol 13(1):20-26.
20. Brown GD. 2006. Dectin-1: A signaling non-TLR pattern-recognition receptor. Nat Rev-Immunol 6:33-43.
21. Brunstedt MR, Sapatnekar S, Rubin KR, Kieswetter KM, Ziats NP, Merritt K, Anderson JM. 1995. Bacteria/blood/material interactions. I. Injected and preseeded slime-forming Staphylococcus epidermidis in flowing blood with biomaterials. J Biomed Mater Res 29(4):455-466.
22. Bryers JD, (editors). 2000. Biofilms, 2nd edn. New York, NY: J. Wiley Interscience.
23. Bryers JD, Ratner BD. 2004. Bioinspired implant materials befuddle bacteria. ASM News 70:232-237.
24. Bryers JD, Ratner BD. 2006. Biomaterials approaches to combating oral biofilms and dental disease. BMC Oral Health 6 (Suppl 1): S15.
25. Busscher HJ, Cowan MM, van der Mei HC. 1992. On the relative importance of specific and non-specific approaches to oral microbial a dhesion. FEMS Microbiol Rev 8(3-4):199-209.
26. Cachia PJ, Hodges RS. 2003. Synthetic peptide vaccine and antibody therapeutic development: Prevention and treatment of Pseudomonas aeruginosa. Biopolymers 71(2):141-168.
27. Camilli A, Bassler BL. 2006. Bacterial small-molecule signaling pathways. Science 311(5764):1113-1116.
28. Casadevall A, Dadachova E, Pirofski LA. 2004. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2(9):695-703.
29. Castelli P, Caronno R, Ferrarese S, Mantovani V, Piffaretti G, Tozzi M, Lomazzi C, Rivolta N, Sala A. 2006. New trends in prosthesis infection in cardiovascular surgery. Surg Infect 7 (Suppl 2): s45-s47.
30. Centers for Disease Control and Prevention Public Health Reports. 2007. Healthcare-associated infections and deaths in U.S. Hospitals, R. Monina Klevens (Editor), March-April, Vol. 1.
31. Chandra J, McCormick TS, Imamura Y, Mukherjee PK, Ghannoum MA. 2007. Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines. Infect Immun 75(5):2612-2620.
32. Chitambar CR, Narasimhan J. 1991. Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology 59(1):3-10.
33. Cohen N, Morisset J, Emilie D. 2004. Induction of tolerance by Porphyromonas gingivalis on APCS: A mechanism implicated in periodontal infection. J Dent Res 83:429-433.
34. Dang JM, Leong KW. 2006. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev 58(4):487-499.
35. Davies DG, Geesey GG. 1995. Regulation of the alginate biosynthesis gene algC in Pseudomonas aeruginosa during biofilm development in continuous culture. Appl Environ Microbiol 61(3):860-867.
36. Davies DG, Chakrabarty AM, Geesey GG. 1993. Exopolysaccharide production in biofilms: Substratum activation of alginate gene expression by Pseudomonas aeruginosa. Appl Environ Microbiol 59(4):1181-1186.
37. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280(5361):295-298.
38. De Smet K, Contreras R. 2005. Human antimicrobial peptides: Defensins, cathelicidins and histatins. Biotechnol Lett 27(18):1337-1347.
39. Donlan RM. 2002. Biofilms: Microbial life on surfaces. Emerg Infect Dis 8(9):881-890.
40. Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, Touw DJ. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J 16(4):749-767. European Centre for Disease Prevention and Control. 2007. Annual epidemiological report on communicable diseases in Europe. (http://www.ecdc.eu.int/index.html), Stockholm, Sweden.
41. Evans RT, Klausen B, Sojar HT, Bedi GS, Sfintescu C, Ramamurthy NS, Golub LM, Genco RJ. 1992. Immunization with Porphyromonas (Bacleroides) gingivalis fimbriae protects against periodontal destruction. Infect Immun 60:2926-2935.
42. Finkelstein RA, Sciortino CV, McIntosh MA. 1983. Role of iron in microbe-host interactions. Rev Infect Dis 5 (Suppl 4): S759-S777.
43. Fischetti VA. 2005. Bacteriophage lytic enzymes: Novel anti-infectives. Trends Microbiol 13(10):491-496.
44. Foster TJ. 2005. Immune evasion by Staphylococci. Nat Rev Microbiol 3:948-958.
45. Fux CA, Stoodley P, Hall-Stoodley L, Costerton JW. 2003. Bacterial biofilms: A diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther 1(4):667-683.
46. Fux CA, Costerton JW, Stewart PS, Stoodley P. 2005. Survival strategies of infectious biofilms. Trends Microbiol 13(1):34-40.
47. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. 2003. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 197(9):1107-1117.
48. Gao Y, Gu W, Chen L, Xu Z, Li Y. 2007. A multifunctional nano device as non-viral vector for gene delivery: In vitro characteristics and transfection. J Control Release 118(3):381-388.
49. Geddes A. 2000. Infection in the twenty-first century: Predictions and postulates. J Antimicrob Chemother 46:873-878.
50. Gilbert P, Allison DG, McBain. AJ. 2002. Biofilms in vitro and in vivo: Do singular mechanisms imply cross-resistance? J Appl Microbiol 92 (Suppl): 98S-110S.
51. Gilboa E, Vieweg J. 2004. Cancer immunotherapy with mRNA transfected dendritic cells. Immunol Rev 199:251-263.
52. Glantz PO, Arnebrant T, Nylander T, Baier RE. 1999. Bioadhesion - A phenomenon with multiple dimensions. Acta Odontol Scand 57(5):238-241.
53. Goldmann O, von Köckritz-Blickwede M, Höltje C, Chhatwal GS, Geffers R, Medina E. 2007. Transcriptome analysis of murine macrophages in response to infection with Streptococcus pyogenes reveals an unusual activation program. Infect Immun 75(8):4148-4157.
54. Gordon S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3:23-35.
55. Gyimesi E, Bankovich AJ, Schuman TA, Goldberg JB, Lindorfer MA, Taylor RP. 2004. Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages. Immunol Lett 95:185-192.
56. Hall-Stoodley L, Stoodley P. 2005. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol 13(7):7-10.
57. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: From the natural environment to infectious diseases. Nat Rev Microbiol 2(2):95-108.
58. Harraghy N, Kerdudou S, Herrmann M. 2007. Quorum-sensing systems in staphylococci as therapeutic targets. Anal Bioanal Chem 387(2):437-444.
59. Hart D. 1997. Dendritic cells: Unique leukocyte populations that control the primary immune response. Blood 90:3245-3287.
60. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. 2004. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10:187-192.
61. Hodgkinson JT, Welch M, Spring DR. 2007. Learning the language of bacteria. ACS Chem Biol 2(11):715-717.
62. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. 2005. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436(25):1171-1175.
63. Høiby N. 2002. Understanding bacterial biofilms in patients with cystic fibrosis: Current and innovative approaches to potential therapies. J Cyst Fibros 1(4):249-254.
64. Hong HA, Ducle H, Cutting SM. 2005. The use of bacterial spore formers as probiotics. FEMS Microbiol Rev 29(4):813-835.
65. Horswill AR, Stoodley P, Stewart PS, Parsek MR. 2007. The effect of the chemical, biological, and physical environment on quorum sensing in structured microbial communities. Anal Bioanal Chem 387(2):371-380.
66. Hu W, Eaton J, Tang L. 2001. Molecular basis of biomaterial-mediated foreign body reactions. Blood 98:1231-1238.
67. Hubbard JA, Lewandowska KB, Hughes MN, Poole RK. 1986. Effects of iron-limitation of Escherichia coli on growth, the respiratory chains and gallium uptake. Arch Microbiol 146(1):80-86.
68. Janeway CJ, Travers P, Walport M, Shlomchik M. 2005. Immunobiology: The immune system in health and disease, 6th edn. New York: Garland Science Publishing.
69. Jarvis R, Bryers JD. 2005. Effects of controlled fibronectin surface orientation on subsequent Staphylococcus epidermidis adhesion. J Biomed Mater Res-A 75:41-55.
70. Jesaitis AJ, Franklin MJ, Berglund D, Sasaki M, Lord CI, Bleazard JB, Duffy JE, Beyenal H, Lewandowski Z. 2003. Compromised host defense on Pseudomonas aeruginosa biofilms: Characterization of neutrophil and biofilm interactions. J Immunol 171(8):4329-4339.
71. Jotwani R, Cutler CW. 2004. Fimbriated Porphyromonas gingivalis is more efficient than fimbria-deficient P. gingivalis in entering human dendritic cells in vitro and induces an inflammatory Th1 effector response. Infect Immun 72:1725-1732.
72. Jotwani R, Pulendran B, Agrawal S, Cutler CW. 2003. Human dendritic cells respond to Porphyromonas gingivaux LPS by promoting Th2 effector response in vitro. Eur J Immunol 33:2980-2986.
73. Jurado RL. 1997. Iron, infections, and anemia of inflammation. Clin Infect Dis 25(4):888-895.
74. Kaneko Y, Thoendel M, Olakanmi O, Britigan BE, Singh PK. 2007. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 117(4):877-888.
75. Keegan ME, Saltzman WM. 2006. Surface-modified biodegradable microspheres for DNA vaccine delivery. Methods Mol Med 127:107-113.
76. Kobayashi T, Takauchi A, van Spriel AB, Vile HA, Hayakawaf M, Shibata Y, Abiko Y, van de Winkel JGJ, Yoshiea H. 2004. Targeting of Porphyromonas gingivalis with a bispecific antibody directed to FcαRI (CD89) improves in vitro clearance by gingival crevicular neutrophils. Vaccine 23:585-594.
77. Krishnamurthy VM, Quinton LJ, Estroffa LA, Metalloa SJ, Isaacs JM, Mizgerd JP, Whitesides GM. 2006. Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide. Biomaterials 27:3663-3674.
78. Kuhn SE, Nardin A, Klebba PE, Taylor RP. 1998. Escherichia coli bound to the primate erythrocyte complement receptor via bispecific monoclonal antibodies are transferred to and phagocytosed by human monocytes in an in vitro model. J Immunol 160:5088-5097.
79. Leibovich SJ, Ross R. 1975. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol 78:71.
80. Leid JG, Shirtliff ME, Costerton JW, Stoodley AP. 2002. Human leukocytes adhere to, penetrate, and respond to Staphylococcus aureus biofilms. Infect Immun 70(11):6339-6345.
81. Leid JG, Willson CJ, Shirtliff ME, Hassett DJ, Parsek MR, Jeffers AK. 2005. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing. J Immunol 175(11):7512-7518.
82. Li M, Lai Y, Villaruz AE, Cha DJ, Sturdevant DE, Otto M. 2007. Gram-positive three-component antimicrobial peptide-sensing system. Proc Natl Acad Sci USA 104(22):9469-9474.
83. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26.
84. Lindorfer MA, Nardin A, Foley PL, Solga MD, Bankovich AJ, Martin EN, Henderson AL, Price CW, Gyimesi E, Wozencraft CP, Goldberg JB, Sutherland WM, Taylor RP. 2001. Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. J Immunol 167:2240-2249.
85. Little SR, Langer R. 2005. Nonviral delivery of cancer genetic vaccines. Adv Biochem Eng Biotechnol 99:93-118.
86. Mah TF, O'Toole GA. 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9(1):34-39.
87. Månsson LE, Melican K, Molitoris BA, Richter-Dahlfors A. 2007. Progression of bacterial infections studied in real time; novel perspectives provided by multiphoton microscopy. Cell Microbiol 10.1111/j.1462-5822.2007. 01019.x.
88. Mantovani A, Sozzani S, Locati M, Allavena P, Sica. A. 2002. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555.
89. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677-686.
90. Martin P, D'Souza D, Martin J, Grose R, Cooper L, Maki R, McKercher SR. 2003. Wound healing in the PU.1 null mouse - tissue repair is not dependent on inflammatory cells. Curr Biol 13:1122.
91. Martinez LR, Casadevall A. 2005. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun 73(10):6350-6362.
92. Matzinger P. 1994. Tolerance, danger, and the extended family. Annu Rev Immunol 12:991-1045.
93. Mekori Y, Metcalfe D. 2000. Mast cells in innate immunity. Immunol Rev 173:131-140.
94. Mittal R, Sharma S, Chhibber S, Harjai K. 2006. Effect of macrophage secretory products on elaboration of virulence factors by planktonic and biofilm cells of Pseudomonas aeruginosa, Comparative Immunology. Microbiol Infect Dis 29:12-26.
95. Mosser DM. 2003. The many faces of macrophage activation. J Leukoc Biol 73:209-212.
96. Narasimhan J, Antholine WE, Chitambar CR. 1992. Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochem Pharmacol 44:2403-2408.
97. Offenbacher S, Barros SP, Singer RE, Moss K, Williams RC, Beck JD. 2007. Periodontal disease at the biofilm-gingival interface. J Periodontol 78(10):1911-1925.
98. Otto M. 2004. Quorum-sensing control in Staphylococci - A target for antimicrobial drug therapy? FEMS Microbiol Lett 241:135-141.
99. Otto M. 2006. Bacterial evasion of antimicrobial peptides by biofilm formation. Curr Top Microbiol Immunol 306:251-258.
100. Pack DW, Hoffman AS, Pun S, Stayton PS. 2005. Design and development of polymers for gene delivery. Nat Rev Drug Discov 4(7):581-593.
101. Parsek MR, Singh PK. 2003. Bacterial biofilms: An emerging link to disease pathogenesis. Annu Rev Microbiol 57:677-701.
102. Persson GR. 2005. Immune responses and vaccination against periodontal infections. J Clin Periodontol 32 (Suppl 6): 39-53.
103. Post JC, Hiller NL, Nistico L, Stoodley P, Ehrlich GD. 2007. The role of biofilms in otolaryngologic infections: Update 2007. Curr Opin Otolaryngol Head Neck Surg 15(5):347-351.
104. Potempa J, Sroka A, Imamura T, Travis J. 2003. Gingipains, the major cysteine proteinases and virulence factors of Porphyromonas gingivalis: Structure, function and assembly of multidomain protein complexes. Curr Protein Pept Sci 4:397-407.
105. Pritchard DI. 2006. Immune modulation by Pseudomonas aeruginosa quorum-sensing signal molecules. Int J Med Microbiol 296(2-3):111-116.
106. Pulendran B, Kumar P, Cutler CW, Mohamadzadeh M, Van Dyke T, Banchereau J. 2001. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 167:5067-5076.
107. Reisner A, Høiby N, Tolker-Nielsen T, Molin S. 2005. Microbial pathogenesis and biofilm development. Contrib Microbiol 12:114-131.
108. Rooijakkers SH, van Strijp JA. 2007. Bacterial complement evasion. Mol Immmunol 44(1-3):23-32.
109. Rosenberg M. 2006. Microbial adhesion to hydrocarbons: Twenty-five years of doing MATH. FEMS Microbiol Lett 262(2):129-134.
110. Roux P, Munter S, Frischknecht F, Herbomel P, Shorte SL. 2004. Focusing light on infection in four dimensions. Cell Microbiol 6(4):333-343.
111. Rumbaugh KP. 2007. Convergence of hormones and autoinducers at the host/pathogen interface. Anal Bioanal Chem 387(2):425-435.
112. Sauer K, Cullen MC, Rickard AH, Zeef LA, Davies DG, Gilbert P. 2004. Characterization of nutrient-induced dispersion in Pseudomonas aeruginosa PAO1 biofilm. J Bacteriology 186(21):7312-7326.
113. Savill J. 1996. Phagocyte recognition of apoptotic cells. Biochem Soc Trans 24:1065-1069.
114. Schmid D, Dengjel J, Schoor O, Stevanovic S, Münz C. 2006. Autophagy in innate and adaptive immunity against intracellular pathogens. J Mol Med 84:194-202.
115. Schwartz B, Karsan A, Bombeli T, Harlan J. 1999. A novel β-1 integrin-dependent mechanism of leukocyte adherence to apoptotic cells. J Immunol 162:4842-4848.
116. Selwitz RH, Ismail AI, Pitts NB. 2007. Dental caries. Lancet 369(9555):51-59.
117. Shankar R, Griesler H. 1996. In: Ratner BD, Hoffman AS, Schoen FJ, Lemons JE, editors. Biomaterials science: An introduction to materials in medicine. New York: Academic Press.
118. Singh PK. 2004. Iron sequestration by human lactoferrin stimulates P. aeruginosa surface motility and blocks biofilm formation. Biometals 17:267-270.
119. Slayton RL, Bryers JD, Milgrom P. 2006. Biotech and biomaterials research to reduce the caries epidemic. BMC Oral Health 6 (Suppl 1): S1.
120. Smith RS, Iglewski BH. 2003. P. aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol 6(1):56-60.
121. Steinman R. 1991. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296.
122. Stewart PS. 2002. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292:107-113.
123. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138.
124. Stout R, Suttles J. 2004. Functional plasticity of macrophages: Reversible adaptation to changing microenvironments. J Leukoc Biol 76:509-513.
125. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. 2005. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 175:342-349.
126. Strevett KA, Chen G. 2003. Microbial surface thermodynamics and applications. Res Microbiol 154(5):329-335.
127. Su XL, Li Y. 2004. Quantum dot biolabeling coupled with immunomagnetic separation for detection of Escherichia coli O157: H. Anal Chem 76(16):4806-4810.
128. Sulakvelidze A, Alavidze Z, Morris JG Jr. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45(3):649-659.
129. Sun D, Accavitti MA, Bryers JD. 2005. Inhibition of biofilm formation by monoclonal antibodies against Staphylococcus epidermidis RP62A accumulation-associated protein. Clin Diagn Lab Immunol 12:93-100.
130. Tang L, Jennings T, Eaton J. 1998. Mast cells mediate acute inflammatory responses to implanted biomaterials. Proc Natl Acad Sci USA 95:8841-8846.
131. Tateda K, Ishii Y, Horikawa M, Matsumoto T, Miyairi S, Pechere JC, Standiford TJ, Ishiguro M, Yamaguchi K. 2003. The Pseudomonas aeruginosa autoinducer N-3-oxododecanoyl homoserine lactone accelerates apoptosis in macrophages and neutrophils. Infect Immun 71(10):5785-5793.
132. Thomson SA, Burrows SR, Misko IS, Moss DJ, Coupar BE, Khanna R. 1998. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: A novel approach to vaccine design. J Virol 72:2246-2252.
133. Tobery TW, Siliciano RF. 1997. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 185:909-920.
134. Tobery T, Siliciano RF. 1999. Cutting edge: Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol 162:639-642.
135. van Kooyk Y, Geijtenbeck TB. 2003. DC-SIGN: Escape mechanism for pathogens. Nat Rev Immunol 3:697-709.
136. van Kooyk Y, Engering A, Lekkerkerker AN, Ludwig IS, Geijtenbeck TB. 2004. Pathogens use carbohydrates to escape immunity induced by dendritic cells. Curr Opin Immunol 16:488-493.
137. Varshavsky A, Turner G, Du F, Xie Y. 2000. Felix Hoppe-Seyler Lecture 2000. The ubiquitin system and the N-end rule pathway. Biol Chem 381:779-789.
138. Verran J, Whitehead K. 2005. Factors affecting microbial adhesion to stainless steel and other materials used in medical devices. Int J Artif Organs 28(11):1138-1145.
139. Vuong C, Kocianova S, Voyich JM, Yao Y, Fischer ER, DeLeo FR, Otto M. 2004. A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence. J Biol Chem 279:54881-54886.
140. Wagner VE, Bryers JD. 2004. Poly(ethylene glycol)-polyacrylate copolymers modified to control adherent monocyte-macrophage physiology: Interactions with attaching Staphylococcus epidermidis or Pseudomonas aeruginosa bacteria. J Biomed Mater Res A 69(1):79-90.
141. Wagner C, Obst U, Hansen GM. 2005. Implant-associated posttraumatic osteomyelitis: Collateral damage by local host defense? Int J Artif Organs 28(11):1172-1180.
142. Wagner VE, Frelinger JG, Barth RK, Iglewski BH. 2006. Quorum sensing: Dynamic response of Pseudomonas aeruginosa to external signals. Trends Microbiol 14(2):55-58.
143. Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, Fessier MB, Malcolm KC, Vasil ML, Nick JA. 2005. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 73(6):3693-3701.
144. Wenzel RP. 2007. Health care-associated infections: Major issues in the early years of the 21st century. Clin Infect Dis 45 (Suppl 1): S85-S88.
145. Wilson C, Clegg R, Leavesley D, Pearcy M. 2005. Mediation of biomaterial-cell interactions by adsorbed proteins: A review. Tissue Eng 11:1-18.
146. Wizemann TM, Adamou JE, Langermann S. 1999. Adhesins as targets for vaccine development. Emerg Infect Dis 5:395-403.
147. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. 1995. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92:11671-11675.
148. Wu L, Estrada O, Zaborina O, Bains M, Shen L, Kohler JE, Patel N, Musch MW, Chang EB, Fu YX, Jacobs MA, Nishimura MI, Hancock RE, Turner JR, Alverdy JC. 2005. Recognition of host immune activation by Pseudomonas aeruginosa. Science 309(5735):774-777.
149. Xavier JB, Picioreanu C, van Loosdrecht MCM. 2005. A general description of detachment for multidimensional modelling of biofilms. Biotechnol Bioeng 91(6):651-669.
150. Xiong YQ, Willard J, Kadurugamuwa JL, Yu J, Francis KP, Bayer AS. 2005. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob Agents Chemother 49(1):380-387.
151. Yang L, Li Y. 2006. Simultaneous detection of Escherichia coli O157:H7 and Salmonella typhimurium using quantum dots as fluorescence labels. Analyst 131(3):394-401.
152. Yongsunthon R, Lower SK. 2006. Force measurements between a bacterium and another surface in situ. Adv Appl Microbiol 58:97-124.
153. Zhao H, Hemmi H, Akira S, Cheng SH, Scheule RK, Yew NS. 2004. Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther 9:241-248.
154. Zimmermann S, Wagner C, Müller W, Brenner-Weiss G, Hug F, Prior B, Obst U, Hänsch GM. 2006. Induction of neutrophil chemotaxis by the quorum-sensing molecule N-(3-oxododecanoyl)-L-homoserine lactone. Infect Immun 74(10):5687-5692.